治疗抑郁症以改善冠心病的生存率:我们学到了什么?
Robert M Carney1, Kenneth E Freedland1, Michael W Rich2
1Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.
Journal of the American College of Cardiology
|July 24, 2024
概括
重度抑郁症会增加心脏事件的风险. 持续的失眠,疲劳和无情,即使在抑郁症治疗后,在冠心病患者中独立预测心脏事件.
科学领域:
- 心脏病学 心脏病学
- 精神病学是一个精神病学.
- 临床研究 临床研究
背景情况:
- 重度抑郁症 (MDD) 是冠心病 (CHD) 患者心脏事件的已知危险因素.
- 以前的临床试验显示,有限的证据表明,治疗MDD改善了这些患者的无心脏事件生存率.
研究的目的:
- 审查证据表明,抑郁症的特定残留症状,即失眠,疲劳和无情,独立预测心脏事件.
- 提出这些持续的症状,而不是抑郁症本身,可能会导致心血管疾病患者的不良影响.
主要方法:
- 审查现有的临床试验数据和科学文献.
- 分析失眠,疲劳和无声症对心脏事件的独立预测价值.
主要成果:
- 在成功治疗抑郁症后,某些症状如失眠,疲劳和厌倦症通常会持续下去.
- 这些残留症状独立地预测了心脏病患者的心脏事件.
- 这一发现可能解释了为什么之前的试验未能显示改善心脏结果,尽管抑郁症症状有所改善.
结论:
- 慢性心血管疾病患者的不良心血管影响可能与持续的失眠,疲劳和无情感有关,无论整体抑郁状态如何.
- 需要针对这些特定症状的干预措施.
- 建议进行进一步的研究,以评估抑郁型心血管疾病患者对这些症状的干预措施的有效性.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
Electroconvulsive Therapy
30
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
30
Heart Failure Drugs: β-Blockers
333
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
333
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Exercise and Cardiovascular Response
769
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
769
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
155
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155


